LYPSAGEMS Latest Share Price (LYPSAGEMS)
TODAY IN ONE LINE
it trades at a P/E of N/A. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
LYPSAGEMS flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Quarterly OutperformanceLatest quarter Sales up 733.4% and Profit up 399.4%
- ●Reasonable ValuationTrading at a moderate P/E of 7.8x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Poor Capital ReturnsLow ROE of 9.5%
Latest LYPSAGEMS News
What changed recently?
Recent events, corporate actions, and announcements.
LYPSAGEMS valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for LYPSAGEMS, framed against the sector median so the premium or discount is obvious at a glance.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
LYPSAGEMS technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for LYPSAGEMS — derived from the latest tape, not yesterday's close.
LYPSAGEMS last traded at ₹4.63 with an intraday range of ₹4.56–₹4.74 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹4.63| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 5.09 | +0.46 | +9.86% |
| R3 | 4.91 | +0.28 | +5.98% |
| R2 | 4.82 | +0.19 | +4.18% |
| R1 | 4.73 | +0.10 | +2.09% |
| PIVOT | 4.64 | 0.01 | 0.29% |
| CURRENT | 4.63 | — | — |
| S1 | 4.55 | -0.08 | -1.80% |
| S2 | 4.46 | -0.17 | -3.60% |
| S3 | 4.37 | -0.26 | -5.69% |
| S4 | 4.19 | -0.44 | -9.58% |
LYPSAGEMS is trading Below CPR, indicating Bearishness
CPR is Average
Day's range: ₹–₹
Trading Inside opening range
LYPSAGEMS financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for LYPSAGEMS — consolidated or standalone — with margins, YoY growth and key ratios inline.
LYPSAGEMS reports its full P&L, balance sheet, cash flow and ratios on this page — current reported EPS of ₹0.59.
| Metric | Mar 2024 | Mar 2025 |
|---|---|---|
| Revenue from Operations | 9 | 17 ▲ 75.9% |
| Sales Growth YoY %Derived | -28.11% | 75.93% |
| Other Income | — | — |
| Total Income | 9 | 17 ▲ 75.9% |
| 9 | 16 ▲ 78.8% | |
| Gross ProfitDerived | 0 | 0 ▲ 7.7% |
| Gross Margin %Derived | 4.08% | 2.50% |
| 33 | 15 ▼ 53.1% | |
| EBITDA (Operating Profit)Derived | -32 | -15 ▲ 53.8% |
| OPM %Derived | -341.94% | -89.76% |
| 0 | 0 ▼ 9.0% | |
| Profit Before Tax (PBT) | -33 | -15 ▲ 53.5% |
| 0 | -0 ▼ 144.6% | |
| Effective Tax %Derived | -0.13% | 0.12% |
| Total Profit for Period | -33 | -15 ▲ 53.6% |
| Net Profit (Owner's PAT)Derived | -33 | -15 ▲ 53.6% |
| Net Profit Margin %Derived | -344.86% | -90.93% |
| PAT Growth YoY %Derived | 25.82% | 53.61% |
| Earnings Per Share (EPS ₹) | -11.09 | -5.15 ▲ 53.6% |
| Diluted Shares Outstanding (Cr) | 3 | 3 ▲ 0.0% |
| Total Expenses (incl. D&A & Interest) | 42 | 32 ▼ 24.4% |
| Material Cost % of RevenueDerived | 97.53% | 105.03% |
| Employee Cost % of RevenueDerived | 0.18% | 0.10% |
| Other Cost % of RevenueDerived | 345.84% | 92.15% |
| Interest Coverage (x)Derived | -3,26,701.00x | — |
| Period | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Trend |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 200 | 38 ▼ 80.8% | 8 ▼ 78.0% | 14 ▲ 66.7% | 13 ▼ 5.9% | 9 ▼ 28.1% | 17 ▲ 75.9% | |
| Sales Growth YoY %Derived | — | -80.85% | -78.04% | 66.73% | -5.92% | -28.11% | 75.93% | |
| Other Income | 0 | — ▼ 100.0% | — | 0 | — ▼ 100.0% | — | — | |
| Total Income | 200 | 38 ▼ 80.8% | 8 ▼ 78.0% | 14 ▲ 66.7% | 13 ▼ 5.9% | 9 ▼ 28.1% | 17 ▲ 75.9% | |
184 | 36 ▼ 80.4% | 8 ▼ 77.3% | 14 ▲ 67.6% | 13 ▼ 6.1% | 9 ▼ 29.2% | 16 ▲ 78.8% | ||
| Gross ProfitDerived | 16 | 2 ▼ 85.7% | 0 ▼ 89.7% | 0 ▲ 38.5% | 0 ▲ 2.3% | 0 ▲ 13.7% | 0 ▲ 7.7% | |
| Gross Margin %Derived | 8.11% | 6.07% | 2.85% | 2.37% | 2.58% | 4.08% | 2.50% | |
1 | 24 ▲ 1965.6% | 26 ▲ 9.6% | 0 ▼ 99.3% | 44 ▲ 25338.8% | 33 ▼ 25.7% | 15 ▼ 53.1% | ||
| EBITDA (Operating Profit)Derived | 15 | -21 ▼ 241.4% | -26 ▼ 20.4% | 0 ▲ 100.6% | -44 ▼ 27712.9% | -32 ▲ 26.0% | -15 ▲ 53.8% | |
| OPM %Derived | 7.54% | -55.63% | -305.03% | 1.13% | -332.15% | -341.94% | -89.76% | |
1 | 0 ▼ 26.3% | 0 ▼ 6.1% | 0 ▼ 35.8% | 0 ▼ 0.4% | 0 ▼ 13.2% | 0 ▼ 9.0% | ||
| Profit Before Tax (PBT) | 14 | -22 ▼ 250.7% | -26 ▼ 18.9% | -0 ▲ 99.6% | -44 ▼ 38544.7% | -33 ▲ 25.9% | -15 ▲ 53.5% | |
0 | 0 ▼ 49.7% | 0 ▼ 34.1% | -0 ▼ 354.5% | 0 ▲ 112.9% | 0 ▲ 1052.8% | -0 ▼ 144.6% | ||
| Effective Tax %Derived | 0.23% | -0.08% | -0.04% | 24.54% | -0.01% | -0.13% | 0.12% | |
| Total Profit for Period | 14 | -22 ▼ 251.2% | -26 ▼ 18.9% | -0 ▲ 99.7% | -44 ▼ 51116.3% | -33 ▲ 25.8% | -15 ▲ 53.6% | |
| Net Profit (Owner's PAT)Derived | 14 | -22 ▼ 251.2% | -26 ▼ 18.9% | -0 ▲ 99.7% | -44 ▼ 51116.3% | -33 ▲ 25.8% | -15 ▲ 53.6% | |
| Net Profit Margin %Derived | 7.21% | -56.92% | -308.12% | -0.61% | -334.23% | -344.86% | -90.93% | |
| PAT Growth YoY %Derived | — | -251.17% | -18.91% | 99.67% | -51,116.26% | 25.82% | 53.61% | |
| Earnings Per Share (EPS ₹) | 4.89 | -7.39 ▼ 251.1% | -8.79 ▼ 18.9% | -0.03 ▲ 99.7% | -14.96 ▼ 49766.7% | -11.09 ▲ 25.9% | -5.15 ▲ 53.6% | |
| Diluted Shares Outstanding (Cr) | 3 | 3 ▲ 0.0% | 3 ▲ 0.0% | 3 ▲ 0.0% | 3 ▲ 0.0% | 3 ▲ 0.0% | 3 ▲ 0.0% | |
| Total Expenses (incl. D&A & Interest) | 185 | 60 ▼ 67.6% | 34 ▼ 42.9% | 14 ▼ 58.8% | 57 ▲ 305.2% | 42 ▼ 26.4% | 32 ▼ 24.4% | |
| Material Cost % of RevenueDerived | — | — | — | 88.53% | 91.93% | 97.53% | 105.03% | |
| Employee Cost % of RevenueDerived | 0.30% | 1.06% | 2.19% | 0.95% | 0.12% | 0.18% | 0.10% | |
| Other Cost % of RevenueDerived | 0.28% | 60.64% | 305.70% | 0.29% | 334.60% | 345.84% | 92.15% | |
| Interest Coverage (x)Derived | 55.43x | -174.67x | -43,320.50x | — | — | -3,26,701.00x | — |
LYPSAGEMS segment analysis : revenue and profit mix.
Disclosed business segments at LYPSAGEMS with their share of revenue and profit, switchable between consolidated and standalone reporting.
LYPSAGEMS discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for LYPSAGEMS.
Our AI distills the core fundamental drivers supporting LYPSAGEMS, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
LYPSAGEMS's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Low P/E ratio of 7.85x and P/B ratio of 0.74x suggest potential undervaluation.
Quarterly sales surged 115% YoY, demonstrating strong revenue momentum recovery.
Debt-to-equity ratio of 0.0079 maintains very manageable leverage for sector.
Promoter holding of 36.37% provides stable governance foundation and alignment.
Strategic Mumbai location provides access to global diamond trading networks.
Key Risks.
Operating margin of -89.80% in latest quarter reflects severe operational distress.
TTM net profit margin of -96.55% indicates persistent and worsening profitability crisis.
ROCE of -45.10% and ROE of -63.00% signal catastrophic capital inefficiency.
Negative free cash flow of -38.02 Cr in Q1 FY2025 indicates acute cash burn.
Zero institutional ownership (FII 0%, DII 0%) signals complete investor confidence collapse.
Flip Conditions.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.29. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
LYPSAGEMS peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — LYPSAGEMS is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
LYPSAGEMS chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for LYPSAGEMS — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
LYPSAGEMS delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for LYPSAGEMS over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in LYPSAGEMS stood at 81.8% of traded volume, against a 20-day average of 77.2%.
LYPSAGEMS announcements: results, concalls, ratings, M&A.
Filings LYPSAGEMS sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
LYPSAGEMS files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 39 documents below.
Name Change
Lypsa Gems & Jewellery Limited has informed the Exchange that the name has been changed from Lypsa Gems & Jewellery Limited to Aurus Gem Corporation…
Name and Symbol Change
LYPSAGEMS: Members of the Exchange are hereby informed that the name of Lypsa Gems & Jewellery Limited shall be changed to AURUS GEM CORPORATION…
Trading Window
Lypsa Gems & Jewellery Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading)…
Disclosure under SEBI Takeover Regulations
Dipan Babulal Patwa has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India…
Press Release
Lypsa Gems & Jewellery Limited has informed the Exchange regarding a press release dated May 29, 2026, titled "Newspaper publication of Financial…
LYPSAGEMS dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue LYPSAGEMS has declared, sequenced by announce and record date.
LYPSAGEMS corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About LYPSAGEMS: business, sector, key facts.
What LYPSAGEMS does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
LYPSAGEMS operates in the Gems Jewellery And Watches industry under the Consumer Durables sector, listed as NSE: LYPSAGEMS, BSE: 534532.
Lypsa Gems & Jewellery Limited is an Indian company specializing in the diamond industry. Established in 1995 and headquartered in Mumbai, the company's core business revolves around the manufacturing and trading of diamonds.
Their manufacturing operations involve the processing and shaping of rough diamonds into polished gems, ready for use in jewelry or other applications. This likely includes various aspects of diamond cutting, polishing, and grading, potentially utilizing advanced technologies to ensure quality and efficiency.
The trading aspect of Lypsa Gems & Jewellery Limited's business involves buying and selling diamonds in the wholesale market. This could include sourcing rough diamonds from various suppliers, processing them, and then selling the finished polished diamonds to jewelry manufacturers, wholesalers, or retailers. The company’s location in Mumbai, a major diamond trading hub, strategically positions them within a well-established network.
The company's success depends on several factors, including its ability to source high-quality rough diamonds at competitive prices, its expertise in diamond manufacturing and grading, its strong relationships with suppliers and buyers, and its capacity to adapt to the fluctuating demands of the global diamond market. The longevity of the company, operating since 1995, suggests a degree of stability and success in navigating the challenges of this competitive industry.
While specific details on their market share, revenue figures, or specific client base are not available from the provided information, the fundamental business model of Lypsa Gems & Jewellery Limited is clear: to participate actively in all stages of the diamond supply chain, from acquisition of raw materials to the distribution of finished products, effectively integrating manufacturing and trading capabilities to secure its position within the Indian diamond market.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AUSOM ENTERPRISE (AUSOMENT) Share PricePeer
- BANARAS BEADS (BANARBEADS) Share PricePeer
- ETHOS (ETHOSLTD) Share PricePeer
- GOLDIAM INTERNATIONAL (GOLDIAM) Share PricePeer
- KALYAN JEWELLERS IND (KALYANKJIL) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about LYPSAGEMS (LYPSAGEMS).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of LYPSAGEMS (LYPSAGEMS)?
The current share price of LYPSAGEMS (LYPSAGEMS) is ₹4.63. Today, the stock has gained by ₹0.04 (0.87%), trading in a range of ₹4.56 to ₹4.74. The stock opened at ₹4.70 with a trading volume of 8,652 shares.
02What is the 52-week high and low price of LYPSAGEMS stock?
The 52-week high price of LYPSAGEMS (LYPSAGEMS) is ₹7.15, while the 52-week low is ₹4.10. Currently trading at ₹4.63, the stock is 12.93% above its 52-week low and 35.24% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
03What is the dividend yield of LYPSAGEMS and when is the next dividend?
LYPSAGEMS offers a dividend yield of 0%, which means for every ₹100 invested at the current price of ₹4.63, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
04How is LYPSAGEMS stock performing today in the market?
LYPSAGEMS stock opened at ₹4.70 and is currently trading at ₹4.63, showing a gain of ₹0.04 (0.87%). The intraday high is ₹4.74 and low is ₹4.56. The trading volume stands at 8,652 shares, indicating moderate market participation today.
05What is the market capitalization of LYPSAGEMS?
LYPSAGEMS has a market capitalization of ₹0, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹4.63) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
06What is the ROE and ROCE of LYPSAGEMS?
LYPSAGEMS has a Return on Equity (ROE) of 9.53% and Return on Capital Employed (ROCE) of 5.26%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
07Which sector and industry does LYPSAGEMS belong to?
LYPSAGEMS operates in the Consumer Durables sector and belongs to the Gems Jewellery And Watches industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
08What is the debt-to-equity ratio of LYPSAGEMS?
LYPSAGEMS has a debt-to-equity ratio of 0.79, which measures the company's financial leverage by comparing total debt to shareholders' equity. This moderate ratio indicates balanced use of debt and equity. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
The data, ratios and commentary about LYPSAGEMS (LYPSAGEMS) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.